United States Patent Office Patented May 5, 1970
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Seco-Steroids C07C)
CPC - C07J - 2021.08 C07J STEROIDS (seco-steroids C07C) Definition statement This place covers: Compounds containing a cyclopenta[a]hydrophenanthrene skeleton (see below) or a ring structure derived therefrom: • by contraction or expansion of one ring by one or two atoms; • by contraction or expansion of two rings each by one atom; • by contraction of one ring by one atom and expansion of one ring by one atom; • by substitution of one or two carbon atoms of the cyclopenta[a]hydrophenanthrene skeleton, which are not shared by rings, by hetero atoms, in combination with the above defined contraction or expansion or not, or; • by condensation with carbocyclic or heterocyclic rings in combination with one or more of the foregoing alterations or not. Preparation of steroids including purification, separation, stabilisation or use of additives unless provided for elsewhere, as specified below. Treatment and modification of steroids provided that • the treatment is not provided for elsewhere and • the resultant product is a compound under the subclass definition. Relationships with other classification places In class C07, in the absence of an indication to the contrary, a compound is classified in the last appropriate place, i.e. in the last appropriate subclass. For example cyclopenta [a] hydrophenantrenes are classified in subclass C07J as steroids and not in subclasses C07C or C07D as carbocyclic or heterocyclic compounds. Subclass C07J is a function-oriented entry for the compounds themselves and does not cover the application or use of the compounds under the subclass definition. For classifying such information other entries in the IPC exist, for example: Subclass A01N: Preservation of bodies of humans or animals or plants or parts thereof; biocides, e.g. -
Research Collection
Research Collection Doctoral Thesis Some reactions in the D-ring of the steroids Author(s): Boyce, Sam Framroze Publication Date: 1958 Permanent Link: https://doi.org/10.3929/ethz-a-000089222 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library Prom. Nr. 2111 SOME REACTIONS IN THE D-RING 0! THE STEROIDS Thesis presented to The Swiss Federal Institute of Technology Zurich for the Degree of Doctor of Technical Science by SAM FRAMROZE BOYCE Indian Citizen Accepted on the recommendation of Prof. Dr. L. Ruzicka Priv. Doz. Dr. H. Heusser The Commercial Printing Press Private Ltd., Bombay 1958 TO THE MEMORY OF MY DEAR PARENTS ACKNOWLEDGEMENTS For giving me the opportunity to carry out this work, for his encouragement and keen interest during its progress, I here express my deep gratitude to Prof. L. Ruzicka. I am also indebted to Prof. L. Ruzicka and Prof. PI. A. Plattner for guidance of this work. My sincere thanks are also due to P. D. Dr. H. Heussor for his continued co-operation and helpful suggestions during the course of this work. To Prof. V. Prelog, I am obliged for the valuable discussions and critical comments. Finally, I am indebted to Prof. M. Giinthard for the infra-red spectra and to Mr. W. Manser for the micro-analysis. m CONTENTS GENERAL INTRODUCTION 1 Pabt I REARRANGEMENT OF a-HALOGENO-20-KETOSTEROIDS Theoretical Part 3 Experimental Part 10 Pabt Ha BASE CATALYSED REACTIONS WITH A16-3 jS-ACETOXY- 14,15 0-EPOXY-5-ALLOETIOCHOLENIC ACID METHYL ESTER Theoretical Part 18 Experimental Part 27 Pabt lib BASE AND ACID CATALYSED REACTIONS WITH A16-3j3- ACETOXY-14,15/3-EPOXY-20-KETO-5-ALLOPREGNENE Theoretical Part .. -
UNITED STATES PATENT OFFICE 2,636,042 WATER-SOLUBLE HORMONE COMPOUNDS Ralph Salkin, Jackson Heights, N.Y., Assignor to S
Patented Apr. 21, 1953 2,636,042 UNITED STATES PATENT OFFICE 2,636,042 WATER-SOLUBLE HORMONE COMPOUNDS Ralph Salkin, Jackson Heights, N.Y., assignor to S. B. Penick and Company, New York, N. Y., a corporation of Delaware No Drawing. Application July 8, 1949 Serial No. 103,759 5 Claims. (C. 260-39.4) 1. 2 My invention relates to an improvement in the ether, and the sulfate is then Salted out of the manufacture of water-soluble compounds of the aqueous solution by the addition of a, caustic estrane series, and in particular it is concerned solution under cooling. The liberated hormone With an improvement in the synthesis of alkali sulfate is extracted into a suitable Solvent, for and alkaline-earth metal salts of the sulfates of 5 instance butanol, pyridine being preferred how the estranes. ever. The hormone sulfate solution is exhaus The estranes to which my invention applies are tively extracted with ether to remove the solvent. steroids having a free hydroxyl group in the The resultant semicrystalline product is recrys 3-position and a hydroxy or keto group in the tallized from a dilute monohydric alcohol. Or 17-position of the molecule, such as estrone, O Water to give the pure sterol.ester. equilin, equilenin, estradiol and similar com In order to get pure ester Salts, I have found pounds. it essential that the tertiary amine-sulfur trioxide These products which are commonly known as adduct be absolutely pure when being reacted With conjugated estrogens can be obtained from nat the hormones. Improved yields and more readily ural sources such as the urine of pregnant mares purifiable light colored granular products result, or of stallions. -
Labeling and Synthesis of Estrogens and Their Metabolites
Labeling and Synthesis of Estrogens and Their Metabolites Paula Kiuru University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry P.O. Box 55, 00014 University of Helsinki, Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science of the University of Helsinki, for public criticism in Auditorium A110 of the Department of Chemistry, A. I. Virtasen Aukio 1, Helsinki, on June 18th, 2005 at 12 o'clock noon Helsinki 2005 ISBN 952-91-8812-9 (paperback) ISBN 952-10-2507-7 (PDF) Helsinki 2005 Valopaino Oy. 1 ABSTRACT 3 ACKNOWLEDGMENTS 4 LIST OF ORIGINAL PUBLICATIONS 5 LIST OF ABBREVIATIONS 6 1. INTRODUCTION 7 1.1 Nomenclature of estrogens 8 1.2 Estrogen biosynthesis 10 1.3 Estrogen metabolism and cancer 10 1.3.1 Estrogen metabolism 11 1.3.2 Ratio of 2-hydroxylation and 16α-hydroxylation 12 1.3.3 4-Hydroxyestrogens and cancer 12 1.3.4 2-Methoxyestradiol 13 1.4 Structural and quantitative analysis of estrogens 13 1.4.1 Structural elucidation 13 1.4.2 Analytical techniques 15 1.4.2.1 GC/MS 16 1.4.2.2 LC/MS 17 1.4.2.3 Immunoassays 18 1.4.3 Deuterium labeled internal standards for GC/MS and LC/MS 19 1.4.4 Isotopic purity 20 1.5 Labeling of estrogens with isotopes of hydrogen 20 1.5.1 Deuterium-labeling 21 1.5.1.1 Mineral acid catalysts 21 1.5.1.2 CF3COOD as deuterating reagent 22 1.5.1.3 Base-catalyzed deuterations 24 1.5.1.4 Transition metal-catalyzed deuterations 25 1.5.1.5 Deuteration without catalyst 27 1.5.1.6 Halogen-deuterium exchange 27 1.5.1.7 Multistep labelings 28 1.5.1.8 Summary of deuterations 30 1.5.2 Enhancement of deuteration 30 1.5.2.1 Microwave irradiation 30 1.5.2.2 Ultrasound 31 1.5.3 Tritium labeling 32 1.6 Deuteration estrogen fatty acid esters 34 1.7 Synthesis of 2-methoxyestradiol 35 1.7.1 Halogenation 35 1.7.2 Nitration of estrogens 37 1.7.3 Formylation 38 1.7.4 Fries rearrangement 39 1.7.5 Other syntheses of 2-methoxyestradiol 39 1.7.6 Synthesis of 4-methoxyestrone 40 1.8 Synthesis of 2- and 4-hydroxyestrogens 41 2. -
REVIEW Steroid Sulfatase Inhibitors for Estrogen
99 REVIEW Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers Atul Purohit and Paul A Foster1 Oncology Drug Discovery Group, Section of Investigative Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK 1School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham B15 2TT, UK (Correspondence should be addressed to P A Foster; Email: [email protected]) Abstract Estrogens and androgens are instrumental in the maturation of in vivo and where we currently stand in regards to clinical trials many hormone-dependent cancers. Consequently,the enzymes for these drugs. STS inhibitors are likely to play an important involved in their synthesis are cancer therapy targets. One such future role in the treatment of hormone-dependent cancers. enzyme, steroid sulfatase (STS), hydrolyses estrone sulfate, Novel in vivo models have been developed that allow pre-clinical and dehydroepiandrosterone sulfate to estrone and dehydroe- testing of inhibitors and the identification of lead clinical piandrosterone respectively. These are the precursors to the candidates. Phase I/II clinical trials in postmenopausal women formation of biologically active estradiol and androstenediol. with breast cancer have been completed and other trials in This review focuses on three aspects of STS inhibitors: patients with hormone-dependent prostate and endometrial 1) chemical development, 2) biological activity, and 3) clinical cancer are currently active. Potent STS inhibitors should trials. The aim is to discuss the importance of estrogens and become therapeutically valuable in hormone-dependent androgens in many cancers, the developmental history of STS cancers and other non-oncological conditions. -
University Microfilms, Inc., Ann Arbor, Michigan ADRENOCORTICAL STEROID PROFILE IN
This dissertation has been Mic 61-2820 microfilmed exactly as received BESCH, Paige Keith. ADRENOCORTICAL STEROID PROFILE IN THE HYPERTENSIVE DOG. The Ohio State University, Ph.D., 1961 Chemistry, biological University Microfilms, Inc., Ann Arbor, Michigan ADRENOCORTICAL STEROID PROFILE IN THE HYPERTENSIVE DOG DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of the Ohio State University By Paige Keith Besch, B. S., M. S. The Ohio State University 1961 Approved by Katharine A. Brownell Department of Physiology DEDICATION This work is dedicated to my wife, Dr. Norma F. Besch. After having completed her graduate training, she was once again subjected to almost social isolation by the number of hours I spent away from home. It is with sincerest appreciation for her continual encouragement that I dedi cate this to her. ACKNOWLEDGMENTS I wish to acknowledge the assistance and encourage ment of my Professor, Doctor Katharine A. Brownell. Equally important to the development of this project are the experience and information obtained through the association with Doctor Frank A. Hartman, who over the years has, along with Doctor Brownell, devoted his life to the development of many of the techniques used in this study. It is also with extreme sincerity that I wish to ac knowledge the assistance of Mr. David J. Watson. He has never complained when asked to work long hours at night or weekends. Our association has been a fruitful one. I also wish to acknowledge the encouragement of my former Professor, employer and good friend, Doctor Joseph W. -
US2940991.Pdf
2,940,991 Paterated Jj Line 4, 1960 United States Patent Office 2 provide easy access to other biologically active steroid compounds. 2,940,991 These and other objects of this invention will become apparent on reading the following description in con METHOD OF EPIMERIZING 11-BROMO junction with the drawings in which: STERODS Figure 1 is a schematic representation of the process Percy L. Juliana, Oak Park, and Arthur Magnani, Wi in accordance with this invention. w X mette, Ill., assignors to The Julian Laboratories, ne, With respect to the following description, it is desired Frankin Park, I., a corporation of Illinois to point out that reduction providing an OH group in the O 12-position results in a mixture of compounds, some Filed Mar. 1, 1957, Ser. No. 643,353 having the OH bonded by a bond in the or position and 7 Claims. (C. 260-397.45) some by a bond in the 6 position. In the starting mate rial triols either the 12c ol or 126 ol compounds or a Rixture thereof may be employed. The structural formu This invention relates to novel steroid compounds and 15 las herein and in the claims are intended to cover both to processes for their preparation. The compounds of the 12c, ols and 12p ols where discussed and/or claimed. this invention are particularly useful as intermediates in It is also desired to point out that the steroid com the preparation of cortical hormones which have useful pounds discussed and claimed exist in either the 3ox,56 therapeutic activity. -
Nomenclature of Steroids
Pure&App/. Chern.,Vol. 61, No. 10, pp. 1783-1822,1989. Printed in Great Britain. @ 1989 IUPAC INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY and INTERNATIONAL UNION OF BIOCHEMISTRY JOINT COMMISSION ON BIOCHEMICAL NOMENCLATURE* NOMENCLATURE OF STEROIDS (Recommendations 1989) Prepared for publication by G. P. MOSS Queen Mary College, Mile End Road, London El 4NS, UK *Membership of the Commission (JCBN) during 1987-89 is as follows: Chairman: J. F. G. Vliegenthart (Netherlands); Secretary: A. Cornish-Bowden (UK); Members: J. R. Bull (RSA); M. A. Chester (Sweden); C. LiCbecq (Belgium, representing the IUB Committee of Editors of Biochemical Journals); J. Reedijk (Netherlands); P. Venetianer (Hungary); Associate Members: G. P. Moss (UK); J. C. Rigg (Netherlands). Additional contributors to the formulation of these recommendations: Nomenclature Committee of ZUB(NC-ZUB) (those additional to JCBN): H. Bielka (GDR); C. R. Cantor (USA); H. B. F. Dixon (UK); P. Karlson (FRG); K. L. Loening (USA); W. Saenger (FRG); N. Sharon (Israel); E. J. van Lenten (USA); S. F. Velick (USA); E. C. Webb (Australia). Membership of Expert Panel: P. Karlson (FRG, Convener); J. R. Bull (RSA); K. Engel (FRG); J. Fried (USA); H. W. Kircher (USA); K. L. Loening (USA); G. P. Moss (UK); G. Popjiik (USA); M. R. Uskokovic (USA). Correspondence on these recommendations should be addressed to Dr. G. P. Moss at the above address or to any member of the Commission. Republication of this report is permitted without the need for formal IUPAC permission on condition that an acknowledgement, with full reference together with IUPAC copyright symbol (01989 IUPAC), is printed. -
United States Patent (19) 11 Patent Number: 4,585,591 Nitta Et Al
United States Patent (19) 11 Patent Number: 4,585,591 Nitta et al. (45) Date of Patent: Apr. 29, 1986 (54) 17B-ETHYNYLSTEROIDs AND PROCESS 56) References Cited FOR PREPARNG SAME U.S. PATENT DOCUMENTS 75) Inventors: Issei Nitta, Machida; Shinichiro 3,023,206 2/1962 Burnet al. ..................... 260/239.55 Fujimori, Yokohama; Toshio Haruyama, Sagamihara; Shinya FOREIGN PATENT DOCUMENTS Inoue, Yamato, all of Japan 845441 8/1960 United Kingdom ............. 260/397.4 73 Assignee: Mitsubishi Chemical Industries, Ltd., OTHER PUBLICATIONS Tokyo, Japan L. A. van Dijck et al., "Synthesis and Reactions of 3-Methoxy-17-Hydroxy-17-Ethynyl-1,3,5(10)-Estra 21 Appl. No.: 325,026 triene', Recueil Journal of the Royal Netherlands Chemical Society, 96,7-8, Jul.-Aug., pp. 200-205 22 Filed: Nov. 25, 1981 (1977). Primary Examiner-Elbert L. Roberts 30 Foreign Application Priority Data Attorney, Agent, or Firm-Oblon, Fisher, Spivak, Dec. 10, 1980 JP Japan ................................ 55-174065 McClelland & Maier Dec. 10, 1980 JP Japan ... ... 55-174.066 Feb. 23, 1981 JP Japan .................................. 56-25307 (57) ABSTRACT Jul. 28, 1981 (JP) Japan ................................ 56-18343 This is disclosed novel intermediates, i.e. 1743-ethynyl steroids, which are useful for the preparation of corti 51) Int. Cl. .................................................. CO7J 1/00 coids such as hydrocortisone and prednisolone, and a 52 U.S. C. ............................ 260/3974; 260/397.45; process for preparing the same. 260/239.55 C, 260/397.5; 260/397.47 58) Field of Search ......................... 260/397.4, 397.45 4 Claims, No Drawings 4,585,591 1 2 17(3-ETHYNYLSTEROIDS AND PROCESS FOR -continued PREPARING SAME CECH BACKGROUND OF THE INVENTION This invention relates to a novel intermediate for use in the preparation of corticoids (adrenocortical hor mones) such as hydrocortisone, prednisolone and the MeO like. -
The Use of Altrenogest to Control Reproductive Function in Beef Cattle" (2004)
Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2004 The seu of altrenogest to control reproductive function in beef cattle Clarence Edward Ferguson Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Animal Sciences Commons Recommended Citation Ferguson, Clarence Edward, "The use of altrenogest to control reproductive function in beef cattle" (2004). LSU Doctoral Dissertations. 3957. https://digitalcommons.lsu.edu/gradschool_dissertations/3957 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. THE USE OF ALTRENOGEST TO CONTROL REPRODUCTIVE FUNCTION IN BEEF CATTLE A Dissertation Submitted to the Graduate Faculty of Louisiana State University and Agricultural and Mechanical College In partial fulfillment of the Requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Animal and Dairy Sciences by Clarence Edward Ferguson B.S., McNeese State University, 1996 M.S. Stephen F. Austin State University, 1999 M.N.A.S., Southwest Missouri State University, 2000 December 2004 ACKNOWLEDGEMENTS The author would like to convey his sincere gratitude to his major professor, Dr. Robert A. Godke for his direction, patience, and commitment to train him as a research scientist. The author believes that the training he received in Dr. Godke’s Program has been and will continue to be an invaluable experience that will aid him in overcoming obstacles later in life. -
Tailed Deer (Odocoileus Virginianus) by Immunoassay of Steroid Hormones Metabolytes in Feces
Open Access Journal of Science Mini Review Open Access A study on reproductive endocrinology of white- tailed deer (Odocoileus virginianus) by immunoassay of steroid hormones metabolytes in feces Volume 2 Issue 4 - 2018 Summary The objective of this study was carried out a documentary review on studies about Rubén Cornelio Montes-Perez monitoring endocrine activity of white-tailed deer (Odocoileus virginianus) by Facultad de Medicina Veterinaria y Zootecnia, Universidad immunoassay of feces to diagnose ovarian cycle activity, sex allocation and pregnancy Autonoma de Yucatan, Mexico diagnostics was conducted. The results indicated that it is feasible to monitor reproductive endocrine activity by estimating gonadic steroid metabolytes in urine and Correspondence: Rubén Cornelio Montes Perez, Facultad feces, although the results are not consistent due to level variations of metabolytes in de Medicina Veterinaria y Zootecnia, Universidad Autonoma de feces and also due to the pregnancy and sex allocation diagnostics efficiency. Several Yucata, Carretera Mérida-Xmatkuil km 15.5, CP. 97315. Merida, factors determine this variability, therefore, it is necessary to optimize technologies Yucatan, Mexico, Tel 52 9992621918, and /or test strategies to standardize sampling methods, to obtain more reliable results. Email [email protected] Keywords: white-tailed deer, steroid metabolytes, endocrinology studies, non- Received: July 06, 2018 | Published: July 19, 2018 invasive methods Introduction ml to day 23 and undetectable values at day 26, which is the average time of the estrous cycle. They concluded that the levels, pattern of Reproduction of white-tailed deer (Odocoileus virgininianus) can changes and individual variation of blood progestin of the white tailed occur all year round in various South American countries; the highest female are similar to those reported for domestic sheep. -
United States Patent Office Patented Aug
3,338,926 United States Patent Office Patented Aug. 29, 1967 1. 2 3,338,926 Sult in an appreciable amount of by-product formation PROCESS FOR THE HYDROLYSIS OF CYCLIC through esterification of free hydroxyl groups on the ACETALS AND KETALS nucleus or in the side chains (producing, for example, 21 Francisco Alvarez, John B. Siddall, and Augusto Ruiz, formoxy steroids which, if they also contain a 17a-hy Palo Alto, Calif., assignors to Syntex Corporation, droxyl group and are later hydrolyzed, will in part un Panamaa, Panama, a corporation of Panama dergo D-homo rearrangement no matter how mild the No Drawing. Filled May 2, 1966, Ser. No. 546,602 base used, or 116-formoxy steroids, which can only be 10 Claims. (C. 260-397.4) hydrolyzed back to the free alcohols under relatively drastic conditions, thus giving rise, again in the case of the This is a continuation-in-part of copending application O 17a-hydroxypregnanes, to an even greater amount of D Ser. No. 460,462, filed June 1, 1965, now abandoned. homo rearrangement), degradation of a dihydroxy-ace This invention relates to a process for the preparation tone side chain, if present, or destruction of acid-sensi of cyclopentanophenanthrene derivatives. tive groups elsewhere in the steroid molecule, or all of More particularly, this invention relates to a novel these, leading to poor yields of free dihydroxy final prod method for the conversion, in good yields and with a 5 uct contaminated with relatively large amounts of un minimum of by-product formation, of cyclic acetal and wanted by-products.